Johnson & Johnson Announces Start of Safety and Immunogenicity Clinical Trial of Ebola Vaccine Regimen in Sierra Leone

By: via Benzinga
Johnson & Johnson (NYSE: JNJ) today announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.